title: Motor disorders and impaired electrical power of pallidal EEG improved by gallic acid in animal model of Parkinson's disease.
abstract: The aim of this study was evaluation the effect of Gallic acid on movement disorders and pallidal electrical power in animal model of Parkinson's Disease (PD). PD is clinically characterized by development of motor disturbances, such as bradykinesia, resting tremors, rigidity and a later loss ofpostural reflexes. Oxidative stress is a hallmark factor where the oxidation of dopamine generates Reactive Oxygen Species (ROS) and an unbalanced production ROS induces neuronal damage, therefor leading the neuronal death. Gallic Acid (GA) and its derivatives are present in the plant kingdom and acts as a potent antioxidant. Wistar male rats divided into seven groups randomly with 8 in each. Animals in all groups except control received 8 microg/2 microL 6-hydroxydopamine dissolved in normal saline contains 0.01% ascorbate or vehicle in right Medial Forbrain Bundle (MFB) and a bipolar wire electrode was implanted in the left globus pallidus nucleus of all animals under stereotaxic surgery. Two weeks later PD was approved by contralateral rotation signs induced by apomorphine and then movements and electrical power of pallidal were evaluated. Motor functions and pallidal electrical power were impaired and GA could improve motor dysfunctions and gamma wave power in parkinsonian rats' significantly with higher dose of GA (200 mg kg(-1)). Present result showed that GA may act as a potent antioxidant and free radical scavenger to reverse motor disorders and pallidal gamma wave power after 6-OHDA neurotoxicity in brain.
authors.affiliation: Department of Physiology, Faculty of Medicine and Physiology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
authors.forename: Maryam Jafar
authors.initials: MJ
authors.lastname: Sameri
authors.forename: Alireza
authors.initials: A
authors.lastname: Sarkaki
authors.forename: Yaghoub
authors.initials: Y
authors.lastname: Farbood
authors.forename: Seyed Mohammad Taghi
authors.initials: SM
authors.lastname: Mansouri
mesh_terms: D018663:Adrenergic Agents / Q000494:pharmacology; D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use; D004195:Disease Models, Animal; D004569:Electroencephalography; D005707:Gallic Acid / Q000494:pharmacology / Q000627:therapeutic use*; D005917:Globus Pallidus / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008474:Medial Forebrain Bundle; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology; D009069:Movement Disorders / Q000188:drug therapy* / Q000503:physiopathology*; D009483:Neuropsychological Tests; D018384:Oxidative Stress; D016627:Oxidopamine / Q000494:pharmacology; D020734:Parkinsonian Disorders / Q000188:drug therapy* / Q000503:physiopathology*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar
chemical_list: D018663:Adrenergic Agents; D000975:Antioxidants; D005707:Gallic Acid; D016627:Oxidopamine